Cargando…

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells

Acute lymphoblastic leukemia (ALL) is characterized by leukemic expansion of lymphoid blasts in hematopoietic tissues. Despite improved therapy only a subset of patients can be cured. Therefore, current research is focusing on new drug-targets. Members of the BCL-2 family and components of the PI3-k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stefanzl, Gabriele, Berger, Daniela, Cerny-Reiterer, Sabine, Blatt, Katharina, Eisenwort, Gregor, Sperr, Wolfgang R., Hoermann, Gregor, Lind, Karin, Hauswirth, Alexander W., Bettelheim, Peter, Sill, Heinz, Melo, Junia V., Jäger, Ulrich, Valent, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620205/ https://www.ncbi.nlm.nih.gov/pubmed/28978065 http://dx.doi.org/10.18632/oncotarget.18810

Ejemplares similares

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
por: Espona-Fiedler, Margarita, et al.
Publicado: (2022)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
por: Heidari, N, et al.
Publicado: (2010)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma
por: Cournoyer, Sonia, et al.
Publicado: (2019)

The PI3-Kinase/mTOR-Targeting Drug NVP-BEZ235 Inhibits Growth and IgE-Dependent Activation of Human Mast Cells and Basophils
por: Blatt, Katharina, et al.
Publicado: (2012)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer
por: Chen, Yu-Hsuan, et al.
Publicado: (2019)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells
por: Sulkshane, Prasad, et al.
Publicado: (2016)

Identification of a Leukemia-Initiating Stem Cell in Human Mast Cell Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2019)

Identification of CD203c as a New Basophil-Specific Flow-Marker in Ph(+) Chronic Myeloid Leukemia
por: Sadovnik, Irina, et al.
Publicado: (2022)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017)

Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma
por: Blatt, Katharina, et al.
Publicado: (2016)

Phenotypic Characterization of Leukemia-Initiating Stem Cells in Chronic Myelomonocytic Leukemia
por: Eisenwort, Gregor, et al.
Publicado: (2021)

Cell death induction by the BH3 mimetic GX15-070 in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2015)

Activity of BKM120 and BEZ235 against Lymphoma Cells
por: Civallero, Monica, et al.
Publicado: (2015)

BEZ235: When Promising Science Meets Clinical Reality
por: Pongas, Georgios, et al.
Publicado: (2016)

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells
por: Peter, Barbara, et al.
Publicado: (2017)

Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018)

Protective autophagy or autophagic death: effects of BEZ235 on chronic myelogenous leukemia
por: Xin, Pengliang, et al.
Publicado: (2019)

The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
por: Yu, Cheng-Chan, et al.
Publicado: (2020)

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph(+) chronic myeloid leukemia
por: Peter, Barbara, et al.
Publicado: (2022)

RAD001 Enhances the Potency of BEZ235 to Inhibit mTOR Signaling and Tumor Growth
por: Nyfeler, Beat, et al.
Publicado: (2012)

Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
por: Berger, Daniela, et al.
Publicado: (2021)

Engraftment in NSG(SCF) mice correlates with the WHO category and prognosis in systemic mastocytosis
por: Willmann, Michael, et al.
Publicado: (2023)

PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
por: Wang, Huanan, et al.
Publicado: (2015)

The synergistic antitumor effect of IL-6 neutralization with NVP-BEZ235 in hepatocellular carcinoma
por: Wang, Yao, et al.
Publicado: (2022)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Combination of BEZ235 and Metformin Has Synergistic Effect on Cell Viability in Colorectal Cancer Cells
por: Kim, Taewan, et al.
Publicado: (2018)

NVP-BEZ235 (Dactolisib) Has Protective Effects in a Transgenic Mouse Model of Alzheimer’s Disease
por: Bellozi, Paula Maria Quaglio, et al.
Publicado: (2019)

Antitumor Efficacy of Liposome-Encapsulated NVP-BEZ235 Combined with Irreversible Electroporation for Head and Neck Cancer
por: Tian, Li, et al.
Publicado: (2019)

BEZ235 impairs gastric cancer growth by inhibition of PI3K/mTOR in vitro and in vivo
por: Füreder, Thorsten, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9p1uf17vs14brluk67s4chq3kp